Inquiry
Quality Antibodies Facilitate Your Discovery
Antibody Humanization
Antibody humanization is a process in biotechnology that involves taking a non-human antibody and modifying it to make it more similar to a human antibody. It is a key tool in the development of new and effective therapeutic antibodies.

Yurogen offers antibody humanization services for multiple species’ antibodies, including mouse, camelid, and rabbit monoclonal antibodies, to human antibodies. Combining the traditional CDR grafting and artificial intelligence-assisted analysis for hot spot prediction, mutation and removal, the final delivered humanized antibodies can achieve good balances among specificity, affinity, and immunogenicity. Yurogen has completed more than 20 antibody humanization projects. Our expertise guarantees a short turnaround time, a competitive price, and the best delivery.
Service Features
Customized Vaccination Strategy

Include DNA immunization, cell immunization and VLP immunization etc.

Physicochemical Analysis and Evaluation of Drugability

One stop analysis including expression levels, aggregation, binding affinity, and thermal stability etc.

Development across Multiple Platforms

Include the immunogenicity evaluation, druggability prediction, humanization, delineating CDR regions and characterization of humanized antibodies.

Procedure
Workflow
PhaseServiceDescriptionTimeline
Stage 0Expression and Production of Chimeric Antibodies

  • Synthesis of variable region genes and construction of recombinant plasmids
  • Expression of chimeric antibodies
  • Antibody functional testing (ELISA, FACS, etc.)
  • Biacore affinity testing
  • SEC-HPLC detection

1 week
Stage IHumanization Sequence Analysis

  • Chimeric antibody sequence analysis
  •  CDR and framework region profiling
  • AI-Assisted humanization model design
  • Identification of key amino acid residues

1 week
Stage IICDR Transplantation

  • Synthesis of variable region genes and construction of recombinant plasmids
  • Antibody production (CHO/293F Cells)
  • Antibody functional testing (ELISA, FACS, etc.)
  • Antibody affinity sorting or determination
  • Specific biological function testing (Optional)

1 week
Stage IIIAffinity Maturation (optional)

  • Feasibility assessment and design of revertant mutations
  • Antibody production
  • Antibody functional testing (ELISA, FACS, etc.)
  • Antibody affinity sorting or determination
  • Physicochemical property evaluation and drugability assessment (Optional)
  • Specific biological function testing (Optional)

1 week
Stage IVHumanized Antibody Expression

  • Amplification and production of selected humanized clones
  • Antibody functional testing (ELISA, FACS, etc.)
  • Biacore affinity testing
  • Physicochemical property evaluation and drugability assessment (Optional)
  • Specific biological function testing (Optional)

1 week
*Note: All the phases are around 5-6 weeks.
Yurogen SMab™ platform can directly deliver chimeric antibodies, and humanization services are available beginning with stage I onwards.